Information Provided By:
Fly News Breaks for December 13, 2018
ONVO
Dec 13, 2018 | 07:07 EDT
H.C. Wainwright analyst Ed Arce started Organovo Holdings with a Buy rating and $2.50 price target. Though early, the therapeutic tissue opportunity is compelling, Arce tells investors in a research note. The analyst views Organovo as the "clear leader in the early, pioneering technology of 3D bioprinting of solid organs."